Ixekizumab Effectiveness and Safety in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Multicenter, Retrospective Observational Study

Chiricozzi, Andrea; Burlando, Martina; Caldarola, Giacomo; Conti, Andrea; Damiani, Giovanni; Simone, Clara De; Dini, Valentina; Malagoli, Piergiorgio; Peccerillo, Francesca; Potenza, Concetta; Scala, Emanuele; Skroza, Nevena; Balato, Anna

doi:10.1007/s40257-019-00490-2

Cited by 36 publications

(43 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This impact of the previous exposure to biologics has already been demonstrated in other observational studies. 6,7 However, this impact of prior biologic therapy differs from the results obtained in clinical trials. 5 This difference between patients observed in routine clinical practice and those observed within clinical trials has already been studied.…”

Section: Safetymentioning

confidence: 99%

See 1 more Smart Citation

The effectiveness and safety of ixekizumab in psoriasis patients under clinical practice conditions: A Spanish multicentre retrospective study

Rivera

Velasco

Vidal

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

The objective of the study was to evaluate efficacy and safety of ixekizumab in psoriasis patients under clinical practice conditions. Observational, retrospective, multicentre study that included patients with ixekizumab from March 2017 to March 2019. ≥ 90% reduction in the Psoriasis Area and Severity Index (PASI 90) and absolute PASI <2 were the parameters used to assess treatment response. Adverse events (AEs) were collected. Of the 301 patients included, 111 were women (36.9%), mean age was 48.5 (±13.5) years. Mean baseline PASI score was 13.5 (±7.7). More than half of the patients (68.5%) had received at least one biological drug before. At 3 months, 208 (76.5%) patients achieved PASI <2 and 156 (57.3%) PASI 90. At 12 months, 130 (73.4%) patients achieved absolute PASI <2 and 104 (58.7%) PASI 90. Multivariate analysis revealed that prior use of biologics was influential in achieving PASI <2 at both 3 and 12 months (OR 2.82, P = .006; OR 9.51, P < .001, respectively). Sixty-five patients (21.59%) exhibited at least one AE, injection site reaction was the most

show abstract

Section: Safetymentioning

confidence: 99%

“…These results are similar to those previously published. [6][7][8][9]11 The most common AE was pain or reaction at the injection site. 18-year-old male, 12 months after starting treatment with ixekizumab (in this case, the patient decided to withdraw treatment with ixekizumab).…”

Section: Safetymentioning

confidence: 99%

The effectiveness and safety of ixekizumab in psoriasis patients under clinical practice conditions: A Spanish multicentre retrospective study

Rivera

Velasco

Vidal

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…(23,24) Similar rapid response results were found in other real-world studies outside the US, where signi cant improvement in disease severity measured by PASI was observed at one-month after IXE initiation and continued to improve at 3-month and at 6-months. (9,19) ,28 In the current study, BSA percentage at IXE initiation and a rapid response to IXE at one month were found to be strongly associated with the 24-month IXE treatment outcomes in the study.…”

Section: Discussionmentioning

confidence: 48%

“…Ixekizumab (Taltz®, IXE), an IL-17 antagonist, was approved in the US on March 22, 2016 for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. (15,16) IXE has demonstrated desired effectiveness in clinical trials (17,18) and in real-world clinical practice, (9,19) however, its speed of onset and long-term impact on patient outcomes and treatment persistence has not yet been assessed in a real-world setting.…”

Section: Introductionmentioning

confidence: 99%

Clinical and Quality of Life Outcomes Among Ixekizumab -Treated Psoriasis Patients in a Real-World Setting: Results from a Single US Dermatology Referral Practice

Tao¹,

Setayeshgar²,

Wang³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Psoriasis is a chronic immune-mediated inflammatory skin condition that has a significant negative impact on the physical, emotional, and psychosocial well-being of those affected. Ixekizumab (IXE) has demonstrated an early and high-level treatment response in the real-world setting. This study aimed to assess the rapidity and long-term disease severity and quality of life (QOL) outcomes among IXE-treated plaque psoriasis patients. Method: A retrospective cohort study was conducted at a single US dermatology referral center. Medical charts were reviewed for adult psoriasis patients starting IXE (index date) between March 22, 2016, and February 28, 2018. Disease severity and QOL data were abstracted up to one-year pre-IXE initiation and up to 35 months post-IXE initiation. Static Physician Global Assessment (sPGA), Body Surface Area (BSA), and Dermatology Life Quality Index (DLQI) were summarized at 1-month post-index and at 3-month intervals. Logistic regressions were performed to evaluate the 1-month response in relation to long-term sPGA, BSA, DLQI outcomes. Subgroup analysis were conducted to compare outcomes among biologic naïve and biologic experienced patients.Results: A total of 153 patients (median age at index: 47.7 years; 65.4% male; 93.5% Caucasian) were included in the study. Majority of patients (69%; n=106) were biologic experienced prior to IXE initiation. In the total study cohort, at 1-month post-index 58.8% of patients achieved sPGA (0,1), 55.9% achieved DLQI (0,1), and 66.9% achieved BSA≤1%. Patients with sPGA (0,1) at 1-month post-index had greater odds of remaining sPGA (0,1) and BSA≤1% at 24-month (sPGA 0,1: OR=10.1; 95% CI: 2.1-47.9; BSA≤1%: OR=13.3; 95% CI: 2.2-80.2). Among patients who achieved sPGA (0,1) at 1-month post-index, the proportion of patients with sPGA (0,1), DLQI (0,1), and BSA≤1% remained largely the same for the 24-month follow-up. Among biologic experienced and naïve patients, more than half achieved sPGA (0,1), DLQI (0,1), and BSA≤1% at 1-month after IXE initiation. Conclusion: This real-word study demonstrated that majority of patients initiating IXE achieved sPGA (0, 1), DLQI (0, 1) and BSA ≤1% targets within the first month of treatment and were able to maintain treatment response for up to 24 months independent of prior biologic exposure.

show abstract

“…Negative effects of increased BMI on clinical response were also reported for adalimumab [ 26 ]. Regarding anti-IL-17 therapy the effectiveness of treatment was similar across bodyweight categories either for ixekizumab or secukinumab, even if a lower trend of PASI 90 and PASI 100 responses was detected in obese patients [ 27 – 29 ]. It is not surprising that we found PASI and DLQI scores <10 mostly associated with biological drugs since all patients were on treatment.…”

Section: Discussionmentioning

confidence: 99%

Patients’ demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasis

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

Ixekizumab Effectiveness and Safety in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Multicenter, Retrospective Observational Study

Cited by 36 publications

References 13 publications

The effectiveness and safety of ixekizumab in psoriasis patients under clinical practice conditions: A Spanish multicentre retrospective study

The effectiveness and safety of ixekizumab in psoriasis patients under clinical practice conditions: A Spanish multicentre retrospective study

Clinical and Quality of Life Outcomes Among Ixekizumab -Treated Psoriasis Patients in a Real-World Setting: Results from a Single US Dermatology Referral Practice

Patients’ demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasis

Contact Info

Product

Resources

About